Back to results
US 2026/0263471 A1Published application
Methods of Treating Myelofibrosis
AssigneeKartos Therapeutics, Inc.
InventorsWayne Rothbaum, Srdan Verstovsek, Richard Levy
Life of this patent
Estimating the term…
Abstract
Methods of treating myelofibrosis using a Mouse double minute 2 homolog (MDM2) inhibitor and a JAK inhibitor as a combination therapy for patients having a suboptimal response to the JAK inhibitor monotherapy.
Claims26
A method for treating myelofibrosis in a human subject who has been previously treated for myelofibrosis with ruxolitinib monotherapy and had a suboptimal response to said previous treatment with ruxolitinib monotherapy comprising concurrent administration to the human of a therapeutically effective amount of navtemadlin or a pharmaceutically acceptable salt thereof and ruxolitinib.
Dependencies are inferred from the claim text.